| Purpose:To observe the clinical curative effect and evaluate the curative effect of Jiangu Pills on the treatment of type 2 diabetic osteoporosis.Emphatically to evaluate the clinical symptoms of Chinese medicine,fasting blood glucose,postprandial blood glucose,glycosylated hemoglobin,calcium,phosphorus,parathyroid hormone,osteocalcin,Carboxy terminal peptide,urinary calcium,1,25-dihydroxyvitamin D,lumbar vertebrae bone mineral density and hip bone mineral density.To assess its clinical efficacy and safety,for further clinical application to provide the appropriate objective basis.Methods:Patients who met the diagnostic criteria for type 2 diabetic osteoporosis were divided into control group and treatment group according to the principle of randomization and control grouping.In the basic treatment and conventional hypoglycemic(in addition to thiazolidinedionate drugs)on the basis of the control group to Alfa calcitonin 0.25ugqd,the treatment group was Alfa calcitonin 0.25 ugqd + strengthening bone pill 5gbid,3 months For a course of treatment,observe 2 courses.To observe the clinical symptoms of the two groups before and after treatment,fasting blood glucose,postprandial blood glucose,glycosylated hemoglobin,calcium,phosphorus,parathyroid hormone,osteocalcin,procollagen amino terminal propeptide,Terminal peptides,urinary calcium,1,25-dihydroxyvitamin D,lumbar spine BMD and hip bone mineral density.SPSS21.0 was used for statistical analysis.Results:Mainly in the following aspects summarize:(1)In the overall efficacy of the disease,the treatment group markedly effective 10(33.33%)cases,effective 17(56.67%)cases,ineffective 3(10.00%)cases,the total effective rate of 90.00%;control group markedly 4(13.33%)cases,Effective 10(33.33%)cases,ineffective 16(53.33%)cases,the total effective rate of 46.67%.According to the statistical analysis,the total effective rate of the treatment group was significantly better than the control group,with comparable(P<0.01).(2)In the total score of TCM clinical symptoms,the total score of the experimental group(19.23 ± 7.66 before treatment;10.53 ± 7.97 after treatment)and the total symptom score of the control group(19.43 ± 7.48 before treatment;17.57 ± 7.95 after treatment)were significantly higher than those before treatment(P<0.01).The improvement of the experimental group was more obvious than that of the control group(P<0.01).Compared with the control group,the clinical symptoms of the experimental group and the experimental group were improved after treatment(P<0.05).The clinical symptoms of the experimental group were improved compared with the control group(P<0.05),especially in the lower back pain,lower extremity pain,lower extremity weakness,dizziness,tinnitus,Shenpi tiredness improved more prominent(P<0.01).(3)In the comparison of glucose metabolism,fasting blood glucose in the control group(8.74 ± 2.48 before treatment;6.82 ± 0.83 after treatment;unit mmol/1),postprandial blood glucose(14.98 ± 3.46 before treatment;9.65 ±1.15 after treatment;unit mmol/l)and glycosylated hemoglobin(before treatment 10.14± 1.89;after treatment 7.26 ± 0.87;unit%)and the experimental group(before treatment 8.36 ± 2.37;after treatment 6.91 ± 0.95;unit mmol/1),postprandial blood glucose(14.47 ± 4.23 before treatment;9.40 ±0.96 after treatment;unit mmol/1)and glycosylated hemoglobin(before treatment 10.18 ± 1.95;after treatment 7.16 ± 0.81;unit%)compared with before treatment significantly improved(P<0.01).There was no significant difference between the two groups after treatment(P>0.05).(4)In the comparison of calcium and phosphorus,the control group of serum calcium(2.29 ± 0.15 before treatment;2.33 ± 0.09 after treatment;unit mmol/1)and experimental group of calcium(2.24 ± 0.16 before treatment;2.31 ± 0.12 after treatment;unit mmol/1)increased after treatment(P<0.05).There was no significant difference between the groups(P>0.05)that the control group of serum phosphorus(1.05 ± 0.14 before treatment;1.06 ± 0.09 after treatment;unit mmol/1)and experimental group of phosphorus(1.05 ± 0.18 before treatment;1.04 ± 0.08 after treatment;unit mmol/l).There was no significant difference between the two groups after treatment in the comparison of calcium and phosphorus(P>0.05).(5)In the comparison of bone metabolism,ALP and 25-hydroxy vitamin D were significantly decreased in the two groups compared with those before treatment(P<0.05).There was no significant difference between the two groups(P>0.05).Compared with the control group,the levels of BGP,PTH and PINP in the treatment group were significantly higher than those in the control group(P<0.01).There was no significant improvement in S-CTx treatment(P>0.05).The levels of BGP,PTH,S-CTx and PINP in the control group were improved(P<0.05)BGP,PTH and PINP had significant advantages(P<0.05)and S-CTx had no significant difference(P>0.05).(6)BMD of the lumbar vertebra(0.74 ± 0.07 before treatment;0.78 ± 0.07 after treatment;unit g/cm2)and the hip(0.72 ± 0.10 before treatment;0.75 ± 0.09 after treatment;unit g/cm2)in the control group and that in the control group of the lumbar vertebra(0.73 ± 0.07 before treatment;0.87 ± 0.07 after treatment;unit g/cm2)and the hip(0.70 ± 0.09 before treatment;0.77 ± 0.08 after treatment;unit g/cm2)was significantly higher than that before treatment(P<0.05).The bone mineral density of the lumbar vertebrae in the treatment group was significantly higher than that in the control group(P<0.01),and the hip bone No difference in density(P>0.05).(7)Safety evaluation:the two groups of patients before and after treatment were no significant adverse reactions,the two groups of patients before and after treatment check blood,urine,fecal routine,liver and kidney function,electrocardiogram,chest radiograph no obvious abnormalities.Conclusion:In the treatment of type 2 diabetic osteoporosis kidney deficiency type,in the Chinese medicine can significantly improve the clinical symptoms of patients;in Western indicators,can reduce urinary calcium excretion,reduce bone calcium loss,increase BGP,PINP Content,promote osteoblast activity increased,increased bone density,increased bone strength,thereby reducing and preventing the development of type 2 diabetic osteoporosis.This product has no liver and kidney toxicity,safe,effective,low price,so that patients have a good compliance,with a very good application prospects.This clinical study for the application of tonifying-kidney and toughening-bone in type 2 diabetic osteoporosis provides the appropriate clinical data,can further expand the scope of treatment and a wide range of applications. |
PDF Full Text Request